Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.

Molecular diagnosis & therapy - 1 Mar 2022

Dong Yiting, Xu Jiachen, Sun Boyang, Wang Jie, Wang Zhijie

Abstract excerpt

INTRODUCTION: Numerous therapeutic agents specifically targeting the mesenchymal-epithelial transition (MET) oncogene are being developed. OBJECTIVE: The aim of the current review was to systematically identify and analyze clinical trials that have evaluated MET inhibitors in various cancer types and to provide an overview of their clinical outcomes. METHODS: An electronic literature search was carried out in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Observational Studies as Topic

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 35266116
DOI: 10.1007/s40291-021-00568-w
PMCID: PMC8942886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.PMID 35266116Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].Semantic proximity Read ↗

Savolitinib: A Promising Targeting Agent for CancerSemantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alterationSemantic proximity Read ↗

MET alterations in NSCLC-Current Perspectives and Future Challenges.Semantic proximity Read ↗

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.Semantic proximity Read ↗

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.Semantic proximity Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.